🔎 Trials Near Me

Home › Multiple Myeloma › Ohio › Cleveland

Multiple Myeloma clinical trials in Cleveland, OH

16 studies for Multiple Myeloma are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

RecruitingPhase 2
  • University Hospitals Cleveland Medical Center, Cleveland
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

RecruitingPhase 2
  • Cleveland Clinic, Cleveland
Ages 18 to 80 · All sexes · Updated Sep 25, 2026 · NCT07149857

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

RecruitingPhase 3
  • University Hospitals Cleveland Medical Center, Cleveland
  • Cleveland Clinic Main Campus, Cleveland
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingPhase 1/2
  • Research Site, Cleveland
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07681596

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

RecruitingPhase 3
  • MetroHealth Medical Center, Cleveland
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

RecruitingPhase 1
  • Cleveland Clinic - Taussig Cancer Institute, Cleveland
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05651932

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

RecruitingPhase 3
  • Research Site, Cleveland
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

RecruitingPhase 3
  • Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05243797

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

RecruitingObservational study
  • University Hospitals Seidman Cancer Center, Cleveland
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT05974150

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

RecruitingObservational studyHealthy volunteers welcome
  • Cleveland Clinic, Cleveland
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

RecruitingPhase 1
  • Cleveland Clinic, Cleveland
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

RecruitingPhase 1/2
  • University Hospitals Cleveland, Cleveland
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685

LMY-920 for Treatment of Relapsed or Refractory Myeloma

RecruitingPhase 1
  • University Hospitals Seidman Cancer Center, Cleveland
Ages 18 and older · All sexes · Updated Oct 18, 2024 · NCT05546723

About Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.

More about Multiple Myeloma on MedlinePlus

Multiple Myeloma trials in other cities

Other studies in Cleveland

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.